Erschienen in:
01.10.2009 | Letter
Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome
verfasst von:
Hennie G Raterman, Alexandre E Voskuyl, Ben AC Dijkmans, Michael T Nurmohamed
Erschienen in:
Arthritis Research & Therapy
|
Ausgabe 5/2009
Einloggen, um Zugang zu erhalten
Excerpt
With great interest, we read the article by Toms and colleagues [
1] in the previous issue of
Arthritis Research & Therapy, in which they assessed prevalences of metabolic syndrome (MetS) in rheumatoid arthritis (RA) patients. Moreover, they identified demographic and clinical factors that may be associated with MetS. Toms and colleagues found prevalences of up to 45% of MetS and demonstrated older age and health status (health assessment questionnaire) to be associated with MetS irrespectively of the definition used. Of most interest, an association between methotrexate (MTX) use and decreased presence of MetS was observed in patients more than 60 years of age. The investigators hypothesized that this may be attributed to a drug-specific effect (and not to an anti-inflammatory effect) either by changing levels of adenosine, which is known to interact with glucose and lipid metabolism, or by an indirect effect mediated through concomitant folic acid administration, thereby decreasing homocysteine levels. …